This analysis shows tipec3 and rac1 expression are independent prognostic factors in lung adenocarcinoma, indicating potential therapeutic targets.
Background: Lung adenocarcinoma (LUAD) remains one of the leading causes of cancer-related mortality worldwide. However, the expression and role of TIPE3 and RAC1 in LUAD are not well characterized. Objective: This study aimed to investigate the expression and clinicopathological significance of TNFAIP8L3 (TIPE3) and RAC1 in LUAD, as well as the relationship between these two proteins. Methods: Immunohistochemistry (IHC) was utilized to detect the expression of TIPE3 and RAC1 in tumor and adjacent normal tissues from 183 LUAD patients. A comprehensive analysis of clinicopathological data and subsequent follow-up outcomes was conducted in relation to TIPE3 and RAC1 expression levels. The correlation between these two proteins was also evaluated. Results: Both TIPE3 and RAC1 expression were upregulated in tumor tissues of LUAD. TIPE3 expression was significantly associated with advanced T stage (p=0.001), N stage (p=0.005), and TNM stage (p=0.001). Similarly, increased RAC1 expression was also associated with advanced T stage (p=0.003), N stage (p=0.003), and TNM stage (p=0.001). Kaplan-Meier survival analysis and Cox regression modeling demonstrated that increased TIPE3 and RAC1 expression were independent prognostic factors for poor outcomes in LUAD. Furthermore, Spearman correlation analysis revealed a positive association between TIPE3 and RAC1 expression (r = 0.305, p < 0.001). Combined expression of TIPE3 and RAC1 improved risk stratification and prognostic prediction in LUAD. Conclusion: TIPE3 and RAC1 serve as potential biomarkers of tumor progression and poor prognosis in LUAD, offering promising targets for future therapeutic interventions.
No takes yet. Share an insight, caveat, or question.
Shi et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: